第二军医大学学报
第二軍醫大學學報
제이군의대학학보
ACADEMIC JOURNAL OF SECOND MILITARY MEDICAL UNIVERSITY
2002年
9期
939-942
,共4页
章卫平%王健民%童书鹏%宋献民%钱宝华%周虹%李红梅%丁晓勤
章衛平%王健民%童書鵬%宋獻民%錢寶華%週虹%李紅梅%丁曉勤
장위평%왕건민%동서붕%송헌민%전보화%주홍%리홍매%정효근
造血生长因子%粒细胞集落刺激因子%粒-巨噬细胞集落刺激因子%外周血%造血干细胞%动员%健康供者
造血生長因子%粒細胞集落刺激因子%粒-巨噬細胞集落刺激因子%外週血%造血榦細胞%動員%健康供者
조혈생장인자%립세포집락자격인자%립-거서세포집락자격인자%외주혈%조혈간세포%동원%건강공자
hematopoietic growth factors%granulocyte-colony stimulating factor%granulocyte-macrophage-colony stimulating factor%peripheral blood%hematopoietic stem cell%mobilization%normal donor
目的:探讨造血生长因子(HGFs)对健康供者外周血干细胞(PBSC)的动员作用,并比较粒细胞集落刺激因子(G-CSF)单用及G-CSF联合粒-巨噬细胞集落刺激因子(GM-CSF)的动员效果.方法:52例健康供者分成G-CSF单用组(34例)及与GM-CSF合用组(18例),分别采用G-CSF(5 μg·kg-1·d-1)及G-CSF(3 μg·kg-1·d-1)+GM-CSF(2 μg·kg-1·d-1),连续皮下注射5~6 d动员,采集PBSC.动员前后动态检测外周血及采集物MNC、CD34+细胞、CFU-GM计数.52例血液病患者接受上述供体动员之PBSC并行异基因PBSC移植(Allo-PBSCT).结果:动员后CD34+细胞及CFU-GM分别较动员前增加10.83及8.7倍,并在第5~6天达到高峰;G-CSF单用及与GM-CSF合用均可有效动员CD34+细胞和CFU-GM,但合用较单用更有效(P<0.05);所有患者接受Allo-PBSCT后均满意获得造血重建;随访观察至今应用HGFs对健康供者无明显不良反应.结论:采用中小剂量G-CSF单用和与GM-CSF合用均能安全、有效动员健康供者PBSC,但以合用更为有效.
目的:探討造血生長因子(HGFs)對健康供者外週血榦細胞(PBSC)的動員作用,併比較粒細胞集落刺激因子(G-CSF)單用及G-CSF聯閤粒-巨噬細胞集落刺激因子(GM-CSF)的動員效果.方法:52例健康供者分成G-CSF單用組(34例)及與GM-CSF閤用組(18例),分彆採用G-CSF(5 μg·kg-1·d-1)及G-CSF(3 μg·kg-1·d-1)+GM-CSF(2 μg·kg-1·d-1),連續皮下註射5~6 d動員,採集PBSC.動員前後動態檢測外週血及採集物MNC、CD34+細胞、CFU-GM計數.52例血液病患者接受上述供體動員之PBSC併行異基因PBSC移植(Allo-PBSCT).結果:動員後CD34+細胞及CFU-GM分彆較動員前增加10.83及8.7倍,併在第5~6天達到高峰;G-CSF單用及與GM-CSF閤用均可有效動員CD34+細胞和CFU-GM,但閤用較單用更有效(P<0.05);所有患者接受Allo-PBSCT後均滿意穫得造血重建;隨訪觀察至今應用HGFs對健康供者無明顯不良反應.結論:採用中小劑量G-CSF單用和與GM-CSF閤用均能安全、有效動員健康供者PBSC,但以閤用更為有效.
목적:탐토조혈생장인자(HGFs)대건강공자외주혈간세포(PBSC)적동원작용,병비교립세포집락자격인자(G-CSF)단용급G-CSF연합립-거서세포집락자격인자(GM-CSF)적동원효과.방법:52례건강공자분성G-CSF단용조(34례)급여GM-CSF합용조(18례),분별채용G-CSF(5 μg·kg-1·d-1)급G-CSF(3 μg·kg-1·d-1)+GM-CSF(2 μg·kg-1·d-1),련속피하주사5~6 d동원,채집PBSC.동원전후동태검측외주혈급채집물MNC、CD34+세포、CFU-GM계수.52례혈액병환자접수상술공체동원지PBSC병행이기인PBSC이식(Allo-PBSCT).결과:동원후CD34+세포급CFU-GM분별교동원전증가10.83급8.7배,병재제5~6천체도고봉;G-CSF단용급여GM-CSF합용균가유효동원CD34+세포화CFU-GM,단합용교단용경유효(P<0.05);소유환자접수Allo-PBSCT후균만의획득조혈중건;수방관찰지금응용HGFs대건강공자무명현불량반응.결론:채용중소제량G-CSF단용화여GM-CSF합용균능안전、유효동원건강공자PBSC,단이합용경위유효.
Objective: To explore the efficiency of hematopoietic growth factors (HGFs) on peripheral blood stem cell (PBSC) mobilization in normal donors. Methods: Granulocyte-colony stimulating factor (G-CSF, 5 μg·kg-1·d-1) was used subcutaneously in 34 donors and G-CSF (3 μg·kg-1·d-1) + granulocyte-macrophage-colony stimulating factor (GM-CSF,2 μg·kg-1·d-1) in 18 donors for 5-6 d. PBSC was harvested with CS-3000 Plus or COBE Spectra blood cell separator. The numbers of MNC, CD34+ cells and CFU-GM were determined during the mobilization. Fifty-two patients with hematologic disease received allogeneic peripheral blood stem cell transplantation (Allo-PBSCT). Results: After mobilization, CD34+ cells and CFU-GM yields increased by 10.83 and 8.7 folds, respectively, and peaked on day 5 of HGFs initiation. Both G-CSF alone and G-CSF + GM-CSF effectively mobilized PBSC, while G-CSF+GM-CSF mobilized CD34+cells and CFU-GM more efficiently than G-CSF alone(P<0.05). Hematopoiesis was well reconstituted in all the patients. No severe toxicity was observed in the normal donors. Conclusion: Our data suggests that both G-CSF alone and G-CSF+GM-CSF at a low dose of 5 μg*kg-1*d-1 can safely and effectively mobilize PBSC, while G-CSF+GM-CSF is superior to G-CSF alone.